Novartis Q4 Earnings Call Highlights

Core Insights - Novartis reported high single-digit sales growth for 2025, achieving a 40.1% core margin two years ahead of schedule, with full-year sales rising 8% and core operating income increasing 14% to CHF 21.9 billion [3][4][6] Financial Performance - In Q4, sales declined by 1%, while core operating income rose by 1%. Excluding R&D-related adjustments, underlying Q4 sales growth would have been approximately 3% [2][6] - For the full year, core EPS increased by 17% to $8.98, and free cash flow grew by 8% to CHF 17.6 billion, marking an all-time high for the company [3][6] Product and Pipeline Momentum - Priority brands such as Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix, and Cosentyx showed strong growth, with Kisqali sales rising 57% to CHF 4.8 billion and Kesimpta sales increasing 36% to $4.4 billion [5][7][15] - Pluvicto achieved $2 billion in global sales with a 42% constant-currency growth, while Leqvio reached blockbuster status with 57% full-year growth [7][15] Pipeline Updates - Novartis highlighted several pipeline developments, including a submission for remibrutinib and updates on the renal portfolio, with a revised timeline for the zigakibart phase III protocol expected in the first half of 2027 [8][9] - Data from the Phase III MANIFEST program for pelabresib provided a path forward for registration, with plans for a new Phase III study targeting patients with high baseline symptom burden [10] 2026 Outlook - The company anticipates low single-digit sales growth for 2026, with a core margin decline of one to two percentage points due to the Avidity deal, describing the year as "a year of two halves" [12][14] - The first half of 2026 is expected to see low single-digit sales decline and low double-digit core operating income decline, while the second half is projected to grow mid-single-digit in sales and mid- to high single-digit in core operating income [14] Capital Allocation - In 2025, Novartis invested over $10 billion in R&D, completed a CHF 15 billion buyback program, and proposed a dividend of CHF 3.70 per share, marking the 29th consecutive dividend increase [16]